Top Companies in Epigenetics

The epigenetics market is projected to reach USD 4.29 billion by 2030 from USD 2.24 billion in 2025, at a CAGR of 13.9% during the forecast period. The growth of the epigenetics market is driven by several factors, such as declining sequencing costs and time, rising demand for epigenetic drugs and epigenetics-based diagnostics, and the expansion of population screening programs. Furthermore, technological advancements in epigenetic research are likely to boost market growth in the coming years.

The epigenetics market is consolidated. The prominent players operating in this market include Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Illumina, Inc. (US), PacBio (US), Danaher (US), Active Motif Inc. (US), Bio-Rad Laboratories, Inc. (US), Promega Corporation (US), Revvity (US), Qiagen (Germany), New England Biolabs (US), Zymo Research Corporation (US), Hologic Diagenode (Germany), and F. Hoffmann-La Roche Ltd. (Switzerland), among others. The key players of this market are mostly focusing on collaborations, acquisitions, partnerships, agreements, expansion, and advancements in epigenetics technology.

To know about the assumptions considered for the study download the pdf brochure

Illumina Inc (US)

In 2024, Illumina, Inc. maintained a preeminent position in the genomics market, capitalizing on a well-established customer base that includes leading pharmaceutical and biotechnology companies, genomic research institutions, and various government laboratories and hospitals. The firm possesses a dominant market share in the next-generation sequencing (NGS) domain, which affords it a competitive edge when exploring adjacent sectors, such as epigenetic sequencing. A notable move in this direction occurred in June 2025, when Illumina announced its acquisition of SomaLogic. This strategic acquisition is poised to bolster Illumina's footprint in the burgeoning epigenetics market and further its multiomics strategy, integrating diverse biological data for enhanced insights into genomics, transcriptomics, proteomics, and epigenomics.

Thermofisher Scientific Inc. (US)

Thermo Fisher Scientific Inc. (US) stands out as a prominent player in the epigenetics market in 2024, driven by a robust and diversified product portfolio, an extensive global footprint, and a strategic focus on both organic and inorganic growth initiatives. Notably, in July 2025, the company secured US Food and Drug Administration (FDA) approval for the Oncomine Dx Express Test, utilizing the Ion Torrent Genexus Dx Integrated Sequencer as an in vitro diagnostic (IVD) assay designed for companion diagnostics (CDx) in tumor profiling applications. Thermo Fisher demonstrates a strong commitment to research and development, channeling significant resources into innovation to address the dynamic needs of its clientele. Their comprehensive global distribution network enhances accessibility and customer support, facilitating the delivery of advanced and reliable epigenetics solutions. This multifaceted strategic approach solidifies Thermo Fisher's position as a leading provider in the epigenetics landscape.

Market Ranking

The epigenetics market is characterized by significant competition, with the leading players capturing approximately 45–50% of the total market share. Illumina, Inc. maintains a dominant position, largely due to its extensive product portfolio that encompasses high-performance instruments, sophisticated bioinformatics software, versatile kits, and comprehensive integrated services. The company's substantial market presence is attributed to its capability to provide high-throughput, high-precision, and cost-effective solutions applicable across a range of epigenetic analyses. Other notable competitors such as Thermo Fisher Scientific Inc., PacBio, and Merck KGaA have also secured considerable portions of the market by emphasizing robust R&D initiatives aimed at developing innovative technologies that enhance sensitivity, resolution, and data analytics capabilities in epigenetics. The emerging growth potential in the Asia Pacific and Latin American regions offers strategic opportunities for these companies to broaden their operational reach and leverage trends such as the rising incorporation of epigenetic biomarkers in diagnostics, personalized medicine, and drug discovery processes. Regional and emerging players represent the remaining 50–55% of the market share, resulting in notable consolidation within the sector.

Related Reports:

Epigenetics Market by Product & Service (Enzymes, Kits & Reagents (Antibodies), Software), Method (DNA Methylation, Histone Modification), Technique (NGS, PCR), Application (Oncology, Immunology, Developmental Biology), End User - Global Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets Inc.
1615 South Congress Ave.
Suite 103,
Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com